DTIL Stock Summary and Trading Ideas (Precision Biosciences | NASDAQ:DTIL)

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Precision Biosciences trades on the NASDAQ stock market under the symbol DTIL.

As of August 20, 2026, DTIL stock price climbed to $8.72 with 420,528 million shares trading.

DTIL has a beta of 1.64, meaning it tends to be more sensitive to market movements. DTIL has a correlation of 0.08 to the broad based SPY ETF.

DTIL has a market cap of $240.69 million. This is considered a Small Cap stock.

Last quarter Precision Biosciences reported $0 in Revenue and -$1.26 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.58.

In the last 3 years, DTIL traded as high as $19.43 and as low as $3.53.

The top ETF exchange traded funds that DTIL belongs to (by Net Assets): VTI, IWM, VXF, IWN, FESM.

DTIL has outperformed the market in the last year with a price return of +81.7% while the SPY ETF gained +20.4%. DTIL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +26.4% and +16.7%, respectively, while the SPY returned +4.2% and -0.9%, respectively.

DTIL support price is $8.14 and resistance is $8.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DTIL shares will trade within this expected range on the day.